Wave Life Sciences reports FY2023 revenue $113.3M; cash runway into Q4 2025; INHBE candidate selected

Wave Life Sciences Ltd.

Cash and equivalents $200.4M at Dec 31, 2023; additional $34M received in Q1 2024; runway expected into Q4 2025.
Full-year revenue $113.3M (2022: $3.6M) driven by GSK and Takeda collaborations; net loss improved to $57.5M from $161.8M.
INHBE lead clinical candidate for obesity selected; GalNAc-siRNA shows potent silencing, weight loss without muscle loss; trial initiation expected Q1 2025.
Proof-of-mechanism data for WVE-006 in AATD expected 2024; WVE-N531 dystrophin data in DMD expected Q3 2024; WVE-003 multi-dose HD data expected Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.